Psychedelics Today

In this episode, Joe interviews Bria Tavakoli, LPCC, MA, MS: a therapist specializing in relational and sex therapy, with a focus on helping clients integrate psychedelic experiences.

She shares her personal journey with psychedelics and how they unlocked deep trauma, allowing her to develop a level of comfort with intimacy, love, and her sexuality. She talks about the parallels between psychedelic journeys and sexual experiences, and how both can be gateways to unexplored parts of ourselves, as well as catalysts for healing and transformation. She discusses society’s cultural shame surrounding our sexuality, why we need to view sexuality from a wellness-based model, and how psychedelics can help couples grow together, and at times, really challenge their relational structures. When asked how to combine sex and psychedelics, she answers, “very carefully.”

She also discusses:

• The immense importance of creating a safe space for couples discussing their intimacy
• How clients reporting sexual concerns is usually a cheat code to determining what their real issues are
• Ethical and practical considerations for combining psychedelics and sex therapy, related to stories of concerning sexual behavior in the space
• Why humor and lightness is so important in this work
• The importance of honoring individual capacity and being true to yourself when exploring new experiences

and more! 

For links, head to the show notes page.

In this episode, Kyle interviews Juan Pablo Cappello: co-founder and former CEO of Nue Life Health, whose assets were subsequently acquired by Beckley Waves.

Cappello discusses the current challenges and controversies facing a ketamine industry that has moved much faster than anyone anticipated, and stresses the need to create industry-wide standards – especially for at-home ketamine – before the government imposes its own standards on us. Citing the Matthew Perry case and other bad behavior from providers, he talks about the risks of overpromising and underdelivering, the lack of integration in the majority of at-home ketamine frameworks, and how profit-driven, subscription model motives have overshadowed patient care and ethical practices.

He also discusses:

• The complications from personal perspectives and passions shifting after a psychedelic experience, and how that can change over time
• The FDA’s recent rejection of MDMA: What would have happened to MDMA if it had been approved?
• Hope for more Native American churches, and what they can learn from the DEA’s denial of Soul Quest
• The story of a bump of cocaine ruining the hope for cannabis to be decriminalized under the Carter administration
• Our current Wild West of gas station CBD, Delta-8, and barely-regulated vapes

and more! 

For links, head to the show notes page. 

In this episode, Kyle interviews Geoff Bathje, Ph.D.: licensed psychologist, researcher, former Full Professor, and co-founder of Sana Healing Collective, a Chicago-based non-profit focusing on ketamine-assisted therapy and psychedelic integration.

He talks about what he feels is one of the largest factors in our mental health crisis: the individualistic and neoliberal lens Western culture has placed on mental health and how it neglects the massive systemic and relational factors that are affecting us all. He digs into how we got so alienated and how psychedelics and non-ordinary states of consciousness can not only help us think critically and solve problems, but also move us out of this individualistic framework of healing and more into a collective one. How do we use psychedelics to fix our relationships and find our community?

He discusses:

• The challenge of knowing when to work for relationships and when to just end them, especially in the afterglow of a big experience
• Group ketamine experience vs. individual, how groups can help facilitators find patterns, and how ketamine works with somatic therapy
• His paper, “Psychedelic integration: An analysis of the concept and its practice” and his visual model of integration showing the different domains of our personal experience
• What he thinks will happen next in drug development: Will therapy be left out after Lykos’ failure with MDMA?
• The importance of moving beyond aggressive criticism and moving into world building

and more! 

For links, head to the show notes page. 

In this episode, Joe interviews Thomas Feegel: co-founder of Beond Ibogaine, an ibogaine treatment and research facility in Cancún, Mexico.

When Feegel first heard of ibogaine 16 years ago, he found that people were having great success, but nobody could recommend where to go for treatment. So he worked to create what was needed: a combination of a hospital, mental health treatment facility, retreat center, and resort, with the proper infrastructure in place, employees with ICU experience, exhaustive HIPAA-compliant admission criteria, regular data collection, and a major focus on safety.

Addressing the recent Rolling Stone article about the tragic death of a patient at Beond in 2022 (interestingly, 2 days after his initial dose), he discusses what he feels was inaccurate, largely related to what could be perceived as a suggestion that there wasn’t enough screening or that corners were cut. With no official reason given for the patient’s death, it brings into question just how safe one can be, especially with people whose bodies and hearts have been through so much. How much hidden harm is created by the stress of PTSD and addiction?

He discusses:

• The complexity of journalism and drawing conclusions from limited information
• The limitations of conventional addiction treatments and the sad numbers around how many people stick with rehab
• The importance of collecting as much data as possible about each patient, at regular intervals, prior to, during, and after the experience
• The need for a regulating group to create standards around admission and administration procedures for ibogaine

and more! 

We’re releasing this episode on Veterans Day because Beond’s program was co-developed by veterans, military medical personnel, and active-duty law enforcement officers who have seen how much ibogaine can help. If you know a vet who is struggling, be sure to let them know what's possible with psychedelic therapy. 

For links, head to the show notes page. 

In this episode, David interviews Floris Wolswijk: senior project manager at Delphi; co-founder of FLO coaching; and founder of Blossom, an online informational hub collecting psychedelic courses, trials, companies, and over 2000 categorized research articles.

When Wolswijk began Blossom, he was barely able to fill a weekly newsletter, and now he’s adding a new study nearly every day, perfectly illustrating the exponential growth in psychedelic research. He talks about why so much research is happening (and why more isn’t), the trends he’s seen, the benefit in research changing people’s minds, and what he hopes for in the future. What can the research community learn from existing real world evidence, and how can retreat centers and underground communities contribute?

He also discusses:

• What culture is like in the Netherlands, where psilocybin truffles are legal
• Drug development and the possibilities of adjusting existing molecules
• What we can learn from the Lykos and FDA situation
• The economics of psychedelics and how insurance will likely be the next big conversation
• His work with FLO coaching, and how coaching, acceptance and commitment therapy, and psilocybin can work together

and more! 

For links, head to the show notes page. 

In this episode, Joe interviews Jessica Tracy: head of sales & partnerships at Enthea, a company that works with employers, unions, and employee assistance programs to be able to offer ketamine-assisted therapy (and psilocybin where it’s legal) to employees.

She talks about her path to psychedelics and how the shifts in her life led her to want to help others, finding Enthea and using her 15 years of experience in healthcare to make an immediate difference. She explains how the process works for an employee of a company Enthea works with, and the importance of evidence-based medical policy and rigorous screening to make sure people are getting the best intervention possible. One of Enthea’s largest clients is Dr. Bronner’s, who reported incredible improvements after employees used the benefit, with a 65% improvement in depression scores and an 86% improvement in PTSD.

She also discusses:

• How psychedelics bring awareness to what we need to work on
• Less-discussed treatment modalities, like electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and stellate ganglion block (SGB)
• The inefficiency of traditional talk therapy: 50% of people only see really good benefits after 20 sessions
• The importance of viewing mental health as individualized care: What else can we offer to people who haven’t been helped by traditional methods?
• The research that she wants to see, like measures in how present or productive people are before and after experiences

and more!

For links, head to the show notes page. 

In this episode, Joe and Kyle finally meet up again for the first episode of Psychedelics Lately: the updated version of the much-missed Psychedelics Weekly, where they’ll meet each month to talk about the most interesting stories in psychedelics.

The main story this month is the fate of Massachusetts’ Question 4: Regulated Access to Psychedelic Substances Initiative (The Natural Psychedelic Substances Act). They discuss what they like about the bill, its opposition, and its support, including actress Eliza Dushku Palandjian, who went from a diagnosis of PTSD and an in-the-psychedelic-closet underground experience to becoming a very public, soon-to-be certified psychedelic facilitator. If you live in Massachusetts, make sure to read about the bill and get out and vote this Tuesday (or now, if you’re registered for early voting).

They also discuss:

• Joe’s recent east coast travels to Harvard and the PhilaDelic conference
• Alfred North Whitehead and Process Philosophy
• The Psychedelics and Pain Association, and Court Wing’s involvement in the first published case report of complex regional pain syndrome being treated with psilocybin
• The scientific community needing to embrace more experientially-based approaches and practices
• The challenge of making meaning out of the mystical

and more! 

For links, head to the show notes page. 

In this episode, Joe interviews Dr. Peter Sjöstedt-Hughes: philosopher, lecturer at the University of Exeter, co-director of the Breaking Convention conference, and author who most recently co-edited Philosophy and Psychedelics: Frameworks for Exceptional Experience.

He discusses how the work of William James and an early psilocybin experience led him to an interest in philosophy and psychedelics, and he dives deep into several philosophical concepts: panpsychism, pantheism, ethical pluralism, teleology, process theology, Whitehead’s fallacy of misplaced concreteness, and more. He believes that science has lost touch with metaphysics – the branch of philosophy that examines the basic structure of reality – and that studying metaphysics will lead to more beneficial experiences with the non-ordinary: If you can understand and frame the experience, you’ll have a much better chance of being able to integrate its lessons.

He discusses:

• The complexity of ethics and the need to ask more philosophical questions
• His book, Neo-Nihilism, which argued that there are no shared objective morals
• The West’s’ obsession with scientism and believing only what can be reducible to matter: Is science honest if it ignores the ineffable?
• The connections between philosophical frameworks and religion: Would studying comparative religion help us better understand each other?
• The need for more experiential research

and more! 

Sjöstedt-Hughes is the co-lead on Exeter’s 12-month postgraduate certificate course, “Psychedelics: Mind, Medicine, and Culture,” and is finalizing his next book, a manual on psychedelics and metaphysics.

For links, head to the show notes page.

In this episode, Joe interviews 4 members of the Penn Psychedelics Collaborative: Co-Founder, Taylor Andrews Flatt, PMHNP; Associate Director, Victor Pablo Acero, Ph.D.; Professor in Fine Arts and Co-Director of the Weitzman School of Design, Jackie Tileston; and Executive Director and Director of the Penn Program for Mindfulness, Michael Baime, MD.

Recorded earlier this month at the PhilaDelic conference – one of the primary initiatives of the PPC – they discuss their paths to psychedelics and why this transdisciplinary collection of faculty, researchers, and clinicians at the University of Pennsylvania was so necessary. Viewing psychedelics from different perspectives (Flatt from nursing, Acero from bioengineering, Tileston from the art and mysticism side of things, and Baime from a more mindfulness point of view), their group is a case study in collaboration – a place where connections can be catalyzed and shared goals can be addressed from different angles. How far can we go when different groups start working together?

They discuss:

• The concept of psychedelics not just being used to treat conditions, but to make us healthier
• Psychedelic art and the idea of the art itself being psychoactive rather than just representations of trips
• The work of David Glowacki and bringing about non-ordinary states of consciousness through VR
• Research into salvia being used to alleviate stroke symptoms
• How a lack of funding can really create focus

and more! 

For links, head to the show notes page.

In this episode, Joe interviews two people on the frontlines of the campaign for Massachusetts' Question 4: The Natural Psychedelic Substances Act: Graham Moore and Community Engagement Director, Jamie Morey.

They discuss the specifics of the initiative, listed on the ballot as the “Limited Legalization and Regulation of Certain Natural Psychedelic Substances,” including the removal of criminal penalties for limited personal use, and the establishment of a regulatory agency that will provide therapeutic access to any of five natural psychedelics (psilocybin, psilocin, DMT, mescaline, and ibogaine). They tell their stories of how they discovered the power of psychedelics, and discuss the work they’re doing, educating a fairly interested – but still very hesitant – public about the bill and the importance of it passing this November.

They talk about:

• The significance of this happening in Massachusetts, especially with the amount of biomedical research happening in Boston
• The story of a member of Baystaters creating a fraudulent persona in a veterans advocacy group to fight against legalization efforts
• The challenge of getting people to publicly support initiatives that deal with illegal substances
• The power of small steps in legislation: Before this bill, MA had the most local measures in the U.S.
• How data collection should be handled at service centers

and more! 

If you live in Massachusetts, learn about the bill here, and make sure to get out and cast your vote in November. 

For links, head to the show notes page.